Abstract:Background: Increases in GPNMB are detectable in FTD-GRN cerebrospinal fluid (CSF) and post-mortem brain, and brains of aged Grn-deficient mice. Although no upregulation of GPNMB is observed in the brains of young Grn-deficient mice, peripheral immune cells of these mice do exhibit this increase in GPNMB. Importantly, the functional significance of GPNMB upregulation in progranulin-deficient states is currently unknown. Given that GPNMB has been discussed as a potential therapeutic target in GRN-mediated neurodegeneration, it is vital for the field to determine what the normal function of GPNMB is in the immune system, and whether targeting GPNMB will elicit beneficial or deleterious effects. Methods: The effects of GPNMB knock-down via antisense oligonucleotide (ASO) were assessed in peripheral blood mononuclear cells (PBMCs) from 25 neurologically healthy controls (NHCs) and age- and sex-matched FTD-GRN patients, as well as peritoneal macrophages (pMacs) from progranulin-deficient (Grn-/-) and B6 mice. Lysosomal function, antigen presentation and MHC-II processing and recycling were assessed, as well as cytokine release and transcription. Results: We demonstrate here that ASO-mediated knockdown of GPNMB increases lysosomal burden and cytokine secretion in FTD-GRN carrier and neurologically healthy controls (NHCs) monocytes. ASO-mediated knockdown of GPNMB in Grn-deficient macrophages decreased lysosomal pan-cathepsin activity and protein degradation.. In addition, ASO-mediated knockdown of GPNMB increased MHC-II surface expression, which was driven by decreased MHC-II uptake and recycling, in macrophages from Grn-deficient females. Finally, ASO-mediated knockdown of GPNMB dysregulated IFNy-stimulated cytokine transcription and secretion by mouse macrophages due to the absence of regulatory actions of the GPNMB extracellular fragment (ECF). Conclusions: Our data herein reveals that GPNMB has a regulatory effect on multiple immune effector functions, including capping inflammation and immune responses in myeloid cells via secretion of its ECF. Therefore, in progranulin-deficient states, the drastic upregulation in GPNMB transcript and protein may represent a compensatory mechanism to preserve lysosomal function in myeloid cells. These novel findings indicate that targeted depletion in FTD-GRN would not be a rational therapeutic strategy because it is likely to dysregulate important immune cell effector functions.

Identification of biological pathways regulated by PGRN and GRN peptide treatments using transcriptome analysis

Progranulin as a therapeutic target in neurodegenerative diseases

Microglial Progranulin: Involvement in Alzheimer’s Disease and Neurodegenerative Diseases

The Role of Pgrn in Alzheimer'S Disease

PGRN deficiency exacerbates, whereas a brain penetrant PGRN derivative protects, GBA1 mutation-associated pathologies and diseases.

Progranulin loss results in sex-dependent dysregulation of the peripheral and central immune system

Lysosomal functions of progranulin and implications for treatment of frontotemporal dementia

Progranulin Protects Against Amyloid Β Deposition and Toxicity in Alzheimer’s Disease Mouse Models

Pathogenic cysteine mutations affect progranulin function and production of mature granulins.

Methods to Investigate the Molecular Basis of Progranulin Actions on Brain and Behavior In Vivo Using Knockout Mice

Structure, Function, and Mechanism of Progranulin; the Brain and Beyond

Progranulin Does Not Bind Tumor Necrosis Factor (TNF) Receptors and is Not a Direct Regulator of TNF-Dependent Signaling or Bioactivity in Immune or Neuronal Cells

An Alternative In Vitro Model Of Neurodegeneration In Ftld-U With Pgrn Mutation

Analysis of the Biomarkers for Neurodegenerative Diseases in Aged Progranulin Deficient Mice

ASO-mediated knockdown of GPNMB in mutant-GRN and Grn-deficient peripheral myeloid cells disrupts lysosomal function and immune responses

Delivering progranulin to neuronal lysosomes protects against excitotoxicity

Progranulinopathy: A diverse realm of disorders linked to progranulin imbalances

Peripheral expression of brain-penetrant progranulin rescues pathologies in mouse models of frontotemporal lobar degeneration

Losing protein in the brain: the case of progranulin

Targeting Progranulin as an Immuno-Neurology Therapeutic Approach

Investigating the Role and Regulation of GPNMB in Progranulin-deficient Macrophages